10 results found.

HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IA Br Clinical Trial using laboratory biomarker analysis; pharmacological study; questionnaire administration; fluorine F 18-clevudine; positron emission tomography/computed tomography

University of Southern California - Recruiting 18 years or older.
- Development of an In Vivo Cell Proliferation Marker for PET Assessment of Chemotherapeutic Response in Cancer.
laboratory biomarker analysis; pharmacological study; questionnaire administration; fluorine F 18-clevudine; positron emission tomography/computed tomography

Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Clinical Trial using questionnaire administration; quality-of-life assessment; management of therapy complications; exercise intervention

University of Southern California - Recruiting 18 years or older.
- Combined Exercise Program for Early Breast Cancer Survivors.
questionnaire administration; quality-of-life assessment; management of therapy complications; exercise intervention

Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Ca Clinical Trial using docetaxel; carboplatin; trastuzumab; pertuzumab; goserelin acetate; therapeutic conventional surgery; whole breast irradiation; quality-of-life assessment; laboratory biomarker analysis; aromatase inhibition therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients With Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated With Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation.
docetaxel; carboplatin; trastuzumab; pertuzumab; goserelin acetate; therapeutic conventional surgery; whole breast irradiation; quality-of-life assessment; laboratory biomarker analysis; aromatase inhibition therapy

Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Ca Clinical Trial using systemic chemotherapy; tamoxifen citrate; anastrozole; exemestane; letrozole

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A PHASE III, RANDOMIZED CLINICAL TRIAL OF STANDARD ADJUVANT ENDOCRINE THERAPY +/-CHEMOTHERAPY IN PATIENTS WITH 1-3 POSITIVE NODES, HORMONE RECEPTOR-POSITIVE AND HER2-NEGATIVE BREAST CANCER WITH RECURRENCE SCORE (RS) OF 25 OR LESS. RXPONDER: A CLINICAL TRIAL RX FOR POSITIVE NODE, ENDOCRINE RESPONSIVE BREAST CANCER.
systemic chemotherapy; tamoxifen citrate; anastrozole; exemestane; letrozole

Estrogen Receptor-positive Breast Cancer, Stage I Breast Cancer, Clinical Trial using tamoxifen citrate; polymerase chain reaction; pharmacological study; gene expression analysis; immunohistochemistry staining method; pharmacogenomic studies; matrix-assisted laser desorption/ionization time of flight mass spectrometry; polymorphism analysis; therapeutic conventional surgery; nucleic acid sequencing; protein analysis

Roswell Park Cancer Institute - Recruiting 18 years or older.
- Pilot Study to Analyze a Novel Mechanism Underlying Response to Tamoxifen Therapy in Breast Cancer Patients.
tamoxifen citrate; polymerase chain reaction; pharmacological study; gene expression analysis; immunohistochemistry staining method; pharmacogenomic studies; matrix-assisted laser desorption/ionization time of flight mass spectrometry; polymorphism analysis; therapeutic conventional surgery; nucleic acid sequencing; protein analysis

Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Ca Clinical Trial using Paclitaxel; Carboplatin; Doxorubicin; Cyclophosphamide; Veliparib

Thomas Jefferson University - Recruiting 18 years or older.
- An Adaptive, Randomized Phase II Trial to Determine Pathologic Complete Response With the Addition of Carboplatin With and Without Veliparib to Standard Chemotherapy in the Neoadjuvant Treatment of Triple-Negative Breast Cancer.
Paclitaxel; Carboplatin; Doxorubicin; Cyclophosphamide; Veliparib

Breast Cancer Clinical Trial using Lapatinib; Trastuzumab; Endocrine Therapy; Paclitaxel

SOLTI Breast Cancer Research Group - Recruiting 18 years or older.
- PAMELA: PAM50 HER2-enriched Phenotype as a Predictor of Early Response to Neoadjuvant Lapatinib Plus Trastuzumab in Stage I to IIIA HER2-positive Breast Cancer.
Lapatinib; Trastuzumab; Endocrine Therapy; Paclitaxel

Breast Cancer Clinical Trial using 9 Peptides from Her-2/neu, CEA, & CTA + poly-ICLC

University of Virginia - Recruiting 18 years or older.
- A Pilot Study of the Immunogenicity of a 9-Peptide Breast Cancer Vaccine Plus Poly-ICLC in Stage IB-IIIA Breast Cancer.
9 Peptides from Her-2/neu, CEA, & CTA + poly-ICLC

Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Brea Clinical Trial using paclitaxel; trastuzumab; doxorubicin hydrochloride; cyclophosphamide; laboratory biomarker analysis; cytology specimen collection procedure

Albert Einstein College of Medicine of Yeshiva University - Recruiting 18 years or older.
- Prospective Tissue Collection in Breast Cancer Patients Receiving Preoperative Systemic Therapy.
paclitaxel; trastuzumab; doxorubicin hydrochloride; cyclophosphamide; laboratory biomarker analysis; cytology specimen collection procedure

Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Ca Clinical Trial using mifepristone; placebo; nab-paclitaxel

University of Chicago - Recruiting 18 years or older.
- A Randomized Phase I Trial of Nanoparticle Albumin Bound Paclitaxel (Nab-paclitaxel, Abraxane) With or Without Mifepristone for Advanced Breast Cancer.
mifepristone; placebo; nab-paclitaxel